Recent Publications

Recent Publications, Chapters and Reviews:

Protein Therapeutics and Tolerance (to Protein Drugs)

  1. Cousens LP, Moise L, De Groot AS. Novel Methods for Addressing Immunogenicity in Therapeutic Enzymes. In A. Rosenberg, B. Demeule (eds.), Biobetters, AAPS Advances. American Association of Pharmaceutical Scientists 2015 in the Pharmaceutical Sciences Series 19, DOI: 10.1007/978-1-4939-2543-8_5
  2. HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. Losikoff PT, Mishra S, Terry F, Gutierrez A, Ardito MT, Fast L, Nevola M, Martin WD, Bailey-Kellogg C,De Groot AS, Gregory SH. J Hepatol. 2015 Jan;62(1):48-55. doi: 10.1016/j.jhep.2014.08.026. Epub 2014 Aug 23.
  3. Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases. Terry FE, Moise L, Martin RF, Torres M, Pilotte N, Williams SA, De Groot AS. Expert Rev Vaccines. 2015 Jan;14(1):21-35. doi: 10.1586/14760584.2015.955478. Epub 2014 Sep 5.
  4. C3d adjuvant effects are mediated through the activation of C3d-specific autoreactive T cells. De Groot AS, Ross TM, Levitz L, Messitt TJ, Tassone R, Boyle CM, Vincelli AJ, Moise L, Martin W, Knopf PM. Immunol Cell Biol. 2015 Feb;93(2):189-97. doi: 10.1038/icb.2014.89. Epub 2014 Nov 11.
  5. H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance.
    Liu R, Moise L, Tassone R, Gutierrez AH, Terry FE, Sangare K, Ardito MT, Martin WD, De Groot AS. Hum Vaccin Immunother. 2015 Jun 19:0. [Epub ahead of print]
  6. CHOPPI: A web tool for the analysis of immunogenicity risk from host cell proteins in CHO-based protein production. Bailey-Kellogg C, Gutiérrez AH, Moise L, Terry F, Martin WD, De Groot AS. Biotechnol Bioeng. 2014 Jun 2. doi: 10.1002/bit.25286.
  7. Opinion. Tregitope Peptides: The Active Pharmaceutical Ingredient (API) of IVIG?  De Groot AS, Cousens L, Mingozzi F, Martin W. Invited Article (Darren Flower, Pedro Reche, Editors): Special Topic: Peptide Immuno-therapeutics and Vaccines, Clinical and Developmental Immunology, December 2013. http://www.hindawi.com/journals/jir/2013/493138/abs/.
  8. Commentary. Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics. Anne S De Groot, Frances Terry, Leslie Cousens and William Martin. Expert Rev. Clin. Pharmacol. Nov 13
  9. Review. T-cell dependent Immunogenicity of Protein Therapeutics: Preclinical Assessment and Mitigation. Leslie Cousens, Vibha Jawa; Michel Awwad; Eric Wakshull; Harald Kropshofer; De Groot AS.  Accepted to Clinical Immunology, August 14, 2013. Full Text
  10. Chapter. Immunogenicity of Therapeutic Fusion proteins: Contributory Factors and Clinical Experience. Chapter in: Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges. Vibha Jawa; Leslie Cousens and De Groot AS,  Stefan R. Schmidt (Editor). John Wiley and Sons, Inc. March 2013. Full Text

Autoimmunity and Tolerance

  1. Modulation of CD8+ T cell responses to AAV vectors in vitro and in vivo with IgG-derived MHC class II epitopes.  Daniel J Hui, Etiena Basner-Tschakarjan, Yifeng Chen, Robert J Davidson, George Buchlis, Mustafa Yazicioglu, Gary C Pien, Jonathan D Finn, Virginia Haurigot, Alex Tai, David W Scott, Leslie P Cousens, Shangzhen Zhou, Annie S De Groot, Federico Mingozzi. Jul 2013. Full Text.
  2. Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. Yan Su, Robert Rossi, Anne S. De Groot, and David W. Scott J. Leukocyte Biology. May 2013
  3. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. Leslie P. Cousens, Yan Su, Elizabeth McClaine, Xin Li, Frances Terry, Robert Smith, Jinhee Lee, William Martin, David W. Scott, Anne S. De Groot.  Experimental Diabetes Research. J Diabetes. May 2013
  4. Epitope recognition in HLA-DR3 transgenic mice immunized to TSH-R protein or peptides. Hidefumi Inaba, Leonard Moise, William Martin, Anne S. De Groot, Joe Desrosiers, Ryan Tassone, George Buchman, Takashi Akamizu,  and Leslie J. De Groot.  Endocrinology. Apr 2013
  5. Editorial. De Groot AS. Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases? Expert Review of Clinical Immunology, December 2013, Vol. 9, No. 12, Pages 1155-1157(doi:10.1586/1744666X.2013.858602) Full Text

Vaccines

  1. Immune camouflage: Relevance to vaccines and human immunology. Anne S De Groot, Lenny Moise, Rui Liu, Andres H Gutierrez, Ryan Tassone, Chris Bailey- Kellogg & William Martin. Hum Vaccin Immunotherapeutics. 2015 Feb.
  2. Preclinical development of HIvax: human survivin Highly Immunogenic vaccinesHoffmann PR, Panigada M, Soprana E, Terry F, Bandar IS, Napolitano A, Rose AH, Hoffmann FW, Ndhlovu LC, Belcaid M, Moise L, De Groot AS, Carbone M, Gaudino G, Matsui T, Siccardi A, Bertino P.
    Hum Vaccin Immunother. 2015 Jun 4:0. [Epub ahead of print]
  3. Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: An accelerated approach toward epitope-driven vaccine development. Abdel-Hady KM, Gutierrez AH, Terry F, Desrosiers J, De Groot AS, Azzazy HM.  Hum Vaccin Immunother. 2014 Jun 24;10(8). [Epub ahead of print] Full Text
  4. Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods. Zhang S, Desrosiers J, Aponte-Pieras JR, DaSilva K, Fast LD, Terry F, Martin WD, De Groot AS, Moise L, Moss SF. PlosOne. 2014 Apr 16. Full Text
  5. Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells. Mishra S, Losikoff PT, Self AA, Terry F, Ardito MT, Tassone R, Martin WD, De Groot AS, Gregory SH. Vaccine. 2014 May 30; Epub 2014 Apr 8.
  6. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. Lu He, Anne S De Groot, Andres H Gutierrez, William D Martin, Lenny Moise and Chris Bailey-Kellogg. BMC Bioinformatics 2014, 15(Suppl 4). Full Text
  7. Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design. De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W. Hum Vaccin Immunother. 2014 Feb Full Text
  8. Immunization with Cross-conserved H1N1 Influenza CD4+ T Cell Epitopes Lowers Viral Burden in HLA DR3 Transgenic Mice. Leonard Moise, Ryan Tassone, Howard Latimer, Frances Terry, Lauren Levitz, John P. Haran, Ted M. Ross, Christine Boyle, William D. Martin, Anne S. De Groot. Hum Vaccin Immunother. 2013 Sep 17;9(10). Full Text
  9. Elevated antigen-specific Th2 type response is associated with the poor prognosis of hand, foot and mouth disease. Wei R, Xu L, Zhang N, Zhu K, Yang J, Yang C, Deng C, Zhu Z, De Groot AS, Altmeyer R, Zeng M, Leng Q. Virus Res. 2013 Jul 22.
  10. Universal H1N1 influenza vaccine development: Identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Moise L, Terry F, Ardito M, Tassone R, Latimer H, Boyle C, Martin WD, De Groot AS.Hum Vaccin Immunother. 2013 Jul 11;9(7). [Epub ahead of print.
  11. Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design. De Groot AS, Artidito, M., Terry, F. Levitz L., Ross T., Moise L., Martin B. Hum Vaccin Immunother. May 2013
  12. The Two-Faced T cell Epitope: Examining the Host-Microbe Interface with JanusMatrix. Lenny Moise, Andres H. Gutierrez, Chris Bailey-Kellogg, Frances Terry, Qibin Leng, Karim M. Abdel Hady, Nathan VerBerkmoes, Marcelo B. Sztein, Phyllis Losikoff, William D. Martin, Alan Rothman, Anne S. De Groot.  Hum Vaccin Immunother. 2013 Apr 12
  13. Proceedings:Selected articles on Computational Vaccinology – ICoVax 2013 Proceedings and Publications: Edited by A De Groot, Y He and P De Groot -.  BMC Bioinformatics 2014
  14. Proceedings. Report from the field: Overview of the Sixth Annual Vaccine Renaissance Conference. Spero D, Levitz L, De Groot AS.  Hum Vaccin Immunother. 2013 Jul;9(7):1555-7. doi: 10.4161/hv.24833. Epub 2013 May 31.
  15. Review. Making Vaccines “On Demand”: A Potential Solution for Emerging Pathogens and Biodefense? De Groot AS, Einck L., Moise L, Chambers M., Ballantyne J., Malone RW, Ardito M, Martin W.  Human Vaccines and Immunotherapy. Accepted for publication June 27, 2013. Full Text